Susan Bell is the author of “DES Daughters: Embodied Knowledge and the Transformation of Women’s Health Politics”
Susan E. Bell is Professor of Sociology and A. Myrick Freeman Professor of Social Sciences at Bowdoin College, Brunswick, Maine. Her specialty is the sociology of health and illness.
For the past ten years she has worked with the Maine Humanities Council to develop and teach seminars in literature and medicine at hospitals and health centers in Maine.
She is the author of “DES Daughters: Embodied Knowledge and the Transformation of Women’s Health Politics” (Temple University Press, 2009).
” Forty years ago, the New England Journal of Medicine published an article about the synthetic estrogen DES that is now recognized as a watershed in the annals of medicine… ”
Compelling need for a precautionary approach to avoid human exposure to BPA during prenatal development
The Science Indicates the Need for a Precautionary Approach
The combination of human-association studies and experimental studies in animals provide compelling evidence that low-dose, prenatal exposures to Bisphenol-A (BPA) can lead to a wide range of later-life health concerns. These health effects encompass a wide range of adverse outcomes, including altered brain development, behavior changes, metabolic changes, adverse reproductive outcomes, and changes in breast and prostate development linked to later-life cancer risk in these organs. This collection of health effects is biologically plausible,138 given BPA’s capacity to mimic estrogen, and to therefore disrupt the delicate process of fetal development that is orchestrated by hormones. While inter-species differences may exist in the absorption and metabolism of BPA, the weight of the compiled evidence suggests that viable routes of exposure to active BPA exist for humans. This indicates a compelling need for a precautionary approach to avoid human exposure to BPA during prenatal development.
A 2013 Report by the Breast Cancer Fund
Protecting Us from BPA = Protecting the Next Generation
” …It was five weeks after surgery to remove and reconstruct my vulva — and life in the Picoult-Ford household was back to normal except for one tiny fact. A large elephant had taken residency in our bed and was snoring loudly…”
Sylvie Le Cossec avait une carrière internationale toute tracée, avant queque sa vie soit ravagée par le Distilbène
Communiqué de Presse
Femme indépendante et brillante à la carrière internationale toute tracée, Sylvie Le Cossec nous raconte comment sa vie a été ravagée par le Distilbène, cette hormone de synthèse prescrite à sa mère pour lui éviter les fausses couches et qui s’est sournoisement immiscée dans son corps et celui de ses enfants.
Deux grossesses pathologiques, un fils polyhandicapé à la vie dévastée, une carrière internationale stoppée, une vie de couple bouleversée, un cancer de l’utérus, un quotidien difficile à gérer…
Ce livre est son histoire, le récit d’une enfance, d’une adolescence, d’une vie pas comme les autres avec en filigrane le distilbène.
Une longue confidence, un tête à tête sincère, intime et exclusif dans lequel tous les sujets seront abordés sans aucun tabou.
Préface du docteur Irène FRACHON, pneumologue de renom au CHU de Brest, à l’origine du scandale du MEDIATOR. Elle soutient également la cause des « filles DES », sensibilisée à la face sombre de cette hormone de synthèse et aux drames en résultant .A l’instar du MEDIATOR se profile, à travers le DISTILBENE, « le spectre de la pharmacodélinquance et les mécanismes de ce que l’on nomme la criminalité à col blanc ».
Video by BreastCancerCare published on 25 Sept 2013
Breast Cancer Care is the only specialist breast cancer support charity working throughout the UK. Their aim is to be there for every person facing a breast cancer diagnosis. Together we can ensure that everyone affected by breast cancer has someone to turn to.
Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels
Due to increased marketing, rates of testosterone prescription in the U.S. tripled between 2000 and 2011…
2013 Study Abstract
Rates of testosterone therapy are increasing and the effects of testosterone therapy on cardiovascular outcomes and mortality are unknown. A recent randomized clinical trial of testosterone therapy in men with a high prevalence of cardiovascular diseases was stopped prematurely due to adverse cardiovascular events raising concerns about testosterone therapy safety.
To assess the association between testosterone therapy and all-cause mortality, myocardial infarction (MI), or stroke among male veterans and to determine whether this association is modified by underlying coronary artery disease.
Design, Setting, and Patients:
A retrospective national cohort study of men with low testosterone levels (<300 ng/dL) who underwent coronary angiography in the Veterans Affairs (VA) system between 2005 and 2011.
Main Outcomes and Measures:
Primary outcome was a composite of all-cause mortality, MI, and ischemic stroke.
Of the 8709 men with a total testosterone level lower than 300 ng/dL, 1223 patients started testosterone therapy after a median of 531 days following coronary angiography. Of the 1710 outcome events, 748 men died, 443 had MIs, and 519 had strokes. Of 7486 patients not receiving testosterone therapy, 681 died, 420 had MIs, and 486 had strokes. Among 1223 patients receiving testosterone therapy, 67 died, 23 had MIs, and 33 had strokes. The absolute rate of events were 19.9% in the no testosterone therapy group vs 25.7% in the testosterone therapy group, with an absolute risk difference of 5.8% (95% CI, −1.4% to 13.1%) at 3 years after coronary angiography. In Cox proportional hazards models adjusting for the presence of coronary artery disease, testosterone therapy use as a time-varying covariate was associated with increased risk of adverse outcomes (hazard ratio, 1.29; 95% CI, 1.04 to 1.58). There was no significant difference in the effect size of testosterone therapy among those with and without coronary artery disease (test for interaction, P = .41).
Conclusions and Relevance:
Among a cohort of men in the VA health care system who underwent coronary angiography and had a low serum testosterone level, the use of testosterone therapy was associated with increased risk of adverse outcomes. These findings may inform the discussion about the potential risks of testosterone therapy.
Rates of testosterone therapy prescription have increased markedly in the United States over the past decade. Annual prescriptions for testosterone increased by more than 5-fold from 2000 to 2011, reaching 5.3 million prescriptions and a market of $1.6 billion in 2011. Professional society guidelines recommend testosterone therapy for patients with symptomatic testosterone deficiency. In addition to improving sexual function and bone mineral density and increasing free-fat mass and strength treatment with testosterone has been shown to improve lipid profiles and insulin resistance and increase the time to ST depression during stress testing.
The effects of testosterone therapy on cardiovascular outcomes and mortality are unknown. Prior clinical studies of testosterone therapy have not detected adverse cardiac events, but these trials were generally focused on intermediate end points, of short duration, and not powered for clinical end points. A recent trial, the Testosterone in Older Men with Mobility Limitations (TOM) trial, conducted in older frail men with a high prevalence of cardiovascular diseases was stopped prematurely due to increased cardiovascular events in the treatment group. The premature termination of the TOM trial and the limitations of the prior studies highlight uncertainty regarding the safety of testosterone therapy in older men with cardiovascular diseases.
To address this gap in knowledge, we evaluated the association between the use of testosterone therapy and all-cause mortality, myocardial infarction (MI), and stroke among male veterans and whether this association was modified by underlying coronary artery disease (CAD).
DES Centrum NL behartigen de belangen van alle generaties die zijn blootgesteld aan DES, ofwel diethylstilbestrol
In 2012 heeft het DES Centrum het screeningsprotocol DES-dochters vernieuwd op basis van de meest recente kennis, een belangrijk startpunt voor goede zorg aan DES-dochters. Goede zorg is echter meer dan alleen medisch goede zorg. Daarom is aan dit screeningsprotocol een set van kwaliteitscriteria toegevoegd. Deze criteria zijn gebaseerd op de wensen en behoeften van DES-dochters en verkregen uit een enquête en twee focusgroepen die onder en met de DES-dochters gehouden zijn.
” I was exposed to DES before I was born. My mother was given the medicine while she lived in a Catholic maternity home in NYC in 1967. They told her it was a necessary vitamin, even though she did not have any issues with her pregnancy.
Nobody told her what DES would do to me, her unborn baby.… ”
Déterminer les risques transgénérationnels du Distilbène
Pour la première fois en France, une étude a été lancée pour permettre de déterminer les risques de cancer du sein chez les filles DES soumises in-utero à l’hormone de synthèse Distilbène®, médicament prescrit aux femmes enceintes jusqu’à la fin des années 70 et sensé prevenir les fausses couches. Anne Levadou, Présidente de l’association Réseau D.E.S. France présente leur étude Distilbène trois générations menée en 2013.